{
    "clinical_study": {
        "@rank": "122780", 
        "acronym": "ZOMAXEPT", 
        "arm_group": {
            "arm_group_label": "Zomacton\u00ae treatment with Zomajet\u00ae Vision X device"
        }, 
        "brief_summary": {
            "textblock": "The study is performed to collect long-term data on the treatment adherence and patient's\n      acceptability when Zomacton\u00ae10 mg is administered with the Zomajet\u00ae Vision X device in\n      patients with a growth hormone deficiency or Turner's syndrome."
        }, 
        "brief_title": "Evaluation of the Adherence and the Patient Acceptability of Zomacton\u00ae Treatment With the Zomajet\u00ae Vision X Device", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Growth Hormone Deficiency", 
            "Turner's Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Turner Syndrome", 
                "Gonadal Dysgenesis", 
                "Primary Ovarian Insufficiency", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with growth hormone deficiency,\n\n               1. Diagnosis of growth hormone deficiency proven by appropriate        exploration\n\n               2. Size \u2264 -2 Standard Deviation (SD) according to the French references\n\n               3. Growth velocity in the previous year inferior to the normal for age\n                  (-1SD) or < 4cm/year\n\n          -  Growth deficiency due to Turner's syndrome\n\n               1. Turner's syndrome confirmed by a karyotype\n\n               2. Patient's size \u2264 -2 SD according to the French references\n\n               3. Bone age < 12 years\n\n          -  Patient who require a minimum of 18 months of treatment.\n\n        Exclusion Criteria:\n\n          -  There are no exclusion criteria except the contraindication for Zomacton\u00ae 10 mg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with a growth hormone deficiency or Turner's syndrome."
            }
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018172", 
            "org_study_id": "000122"
        }, 
        "intervention": {
            "arm_group_label": "Zomacton\u00ae treatment with Zomajet\u00ae Vision X device", 
            "intervention_name": "somatropin", 
            "intervention_type": "Drug", 
            "other_name": "Zomacton\u00ae"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toulouse", 
                    "country": "France"
                }, 
                "name": "H\u00f4pital des Enfants, CHU de Toulouse"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_contact_backup": {
            "last_name": "There may be other sites in this country"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: The Commission nationale de l\u2019informatique et des libert\u00e9s", 
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Ratio between actual duration of administration and total duration recommended by physician", 
            "measure": "Rate of overall treatment adherence", 
            "safety_issue": "No", 
            "time_frame": "Up to 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}